Bridgeway Capital Management, LLC Reneo Pharmaceuticals, Inc. Transaction History

Bridgeway Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$5.44 - $8.13 $184,307 - $275,444	33,880 Added 58.92%	91,380 $696,000
Q2 2023 Aug 14, 2023	BUY	$5.44 - $10.5 $176,800 - $341,250	32,500 Added 130.0%	57,500 $377,000
Q1 2023 May 15, 2023	SELL	$2.44 - $6.42 $109,800 - $288,900	-45,000 Reduced 64.29%	25,000 $149,000
Q4 2022 Feb 14, 2023	BUY	$1.8 - $3.52 $45,000 - $88,000	25,000 Added 55.56%	70,000 $163,000
Q3 2022 Nov 14, 2022	SELL	$2.35 - $4.85 $58,750 - $121,249	-25,000 Reduced 35.71%	45,000 $151,000
Q2 2022 Aug 15, 2022	SELL	$1.96 - $3.04 $58,800 - $91,200	-30,000 Reduced 30.0%	70,000 $186,000
Q3 2021 Nov 15, 2021	BUY	$6.28 - $11.07 $628,000 - $1.11 Million	100,000 New	100,000 $745,000

31M

50.8K

Ticker RPHM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,479,600
Market Cap $41.1M
Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...

Get notified when there are updates to the investment portfolio of Bridgeway Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bridgeway Capital Management, LLC with notifications on news.